Sky Century Investment (SKYI) Current Deferred Revenue (2025 - 2026)
Sky Century Investment's (SKYI) quarterly Current Deferred Revenue came in at $26584.0 in Q2 2026, up 1816.65% year-on-year from $1387.0 in Q2 2025, and up 92.62% on a QoQ basis from $13801.0 in Q1 2026.
Sky Century Investment (SKYI) Current Deferred Revenue (2025 - 2026) Analysis & Trends
Sky Century Investment (SKYI) has 2 years of Current Deferred Revenue data on file, last reported at $26584.0 in Q2 2026.
- On a quarterly basis, Current Deferred Revenue rose 1816.65% year-over-year to $26584.0 in Q2 2026; TTM through May 2026 was $26584.0, a 1816.65% increase from a year earlier, with the FY2025 full-year figure at $27550.0, changed N/A from the prior year.
- Current Deferred Revenue for Q2 2026 stood at $26584.0, up from $13801.0 in the prior quarter.
- Over the last five years, Current Deferred Revenue for SKYI reached as high as $27550.0 in Q3 2025 and fell as low as $1387.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Sky Century Investment | 1.06 Mn | 1.06 Mn | 26,045.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | 26,584.00 |
| Feb 28, 2026 | 13,801.00 |
| Nov 30, 2025 | 23,998.00 |
| Aug 31, 2025 | 27,550.00 |
| May 31, 2025 | 1,387.00 |